ArticleFrontiers in oncology2023

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report.

Xiaoting Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.